City
Epaper

Dr Reddy's Laboratories announces commercial launch of anti-COVID-19 drug 2-DG

By ANI | Updated: June 28, 2021 11:40 IST

Dr. Reddy's Laboratories Limited on Monday announced the commercial launch of 2-deoxy-D-glucose (2-DG), an anti-COVID-19 drug.

Open in App

Dr. Reddy's Laboratories Limited on Monday announced the commercial launch of 2-deoxy-D-glucose (2-DG), an anti-COVID-19 drug.

With the Maximum Retail Price (MRP) of each sachet fixed at Rs 990, the drug will be supplied to major governments as well as private hospitals across the country, said an official release.

In the initial weeks, the company will make the drug available in hospitals across metros and Tier 1 cities and subsequently expand coverage to the rest of India with a subsidised rate offered to government institutions.

2-DG manufactured by Dr Reddy's has a purity of 99.5 per cent and is being sold commercially under the brand name 2DGTM.

2-DG, an oral drug was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy's.

It can be administered only upon prescription and under the supervision of a qualified physician to hospitalised moderate to severe COVID-19 patients as an adjunct therapy to the existing standard of care.

The emergency use approval for anti-COVID-19 therapeutic application of the drug was granted on May 1, 2021.

Dr G Satheesh Reddy, Secretary Department of Defence (R&D) and Chairman, DRDO said: "We are pleased to have worked closely with our long-term industry partner Dr Reddy's Laboratories, Hyderabad, for testing 2-DG as therapeutic application in the treatment of COVID-19 patients. DRDO has been contributing in fight against the COVID-19 pandemic with its spin-off technologies."

Satish Reddy, Chairman, Dr. Reddy's said, "2-DG is yet another addition to our COVID-19 portfolio that already covers the full spectrum of mild to moderate and severe conditions and includes a vaccine. We are extremely pleased to have partnered with DRDO in our collective fight against the COVID-19 pandemic."

The 2-DG drug comes in powder form in the sachet, which is taken orally by dissolving it in water.

It accumulates in the virus-infected cells and prevents virus growth by stopping viral synthesis and energy production. Its selective accumulation in virally infected cells makes this drug unique.

The drug reportedly reduces a patient's average recovery time by two and a half days and oxygen demand by upto 40 per cent, the Union Health Ministry said.

( With inputs from ANI )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: Institute of Nuclear Medicine & Allied SciencesindiaHyderabadDefence Research And Development OrganisationNagarDefence research & development organisationHyderIndiUk-indiaThe directorate for defense research and developmentRepublic of india
Open in App

Related Stories

MaharashtraOver 10,000 Pakistani Nationals Traced in Maharashtra and Delhi Post-Palgham Terror Attack

MumbaiViral Sighting of Tesla Cybertruck Near Mumbai Stirs EV Enthusiasm (Photos)

EntertainmentSouth Actor Mahesh Babu Summoned by ED in Money Laundering Case

NationalPM Narendra Modi Discusses Tech and Innovation Collaboration With Elon Musk

TechnologyGoogle Layoffs: Indian Employees in Hyderabad and Bengaluru Likely to Be Affected

National Realted Stories

NationalMarket valuation of six top 10 firms jumps by Rs 1.18 lakh crore this week

NationalMP CM announces 55% pc DA for state employees at par with Centre

NationalApple farming in K'taka, saffron in Kerala: PM Modi showcases India's green success stories

National'We are still paying price', Rashid Alvi backs Mani Shankar Aiyar’s partition remarks

NationalWon't ally with any political parties, people wanting change may join Jan Suraaj: Prashant Kishor